These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 19102357

  • 1. A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer.
    Nakajima Y, Suzuki T, Haruki S, Ogiya K, Kawada K, Nishikage T, Nagai K, Kawano T.
    Hepatogastroenterology; 2008; 55(86-87):1631-5. PubMed ID: 19102357
    [Abstract] [Full Text] [Related]

  • 2. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
    Tanaka T, Fujita H, Sueyoshi S, Tanaka Y, Sasahara H, Mori N, Nagano T, Yamana H, Shirouzu K.
    Chemotherapy; 2007; 53(6):449-53. PubMed ID: 17952006
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S, Hosokawa A, Yoshita H, Ueda Y, Ueda A, Mihara H, Ando T, Fujinami H, Nishikawa J, Ogawa K, Minemura M, Sugiyama T.
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A combined therapy with docetaxel and nedaplatin for relapsed and metastatic esophageal carcinoma.
    Matsumoto H, Hirabayashi Y, Kubota H, Murakami H, Higashida M, Haruma K, Hiratsuka J, Nakamura M, Hirai T.
    Anticancer Res; 2012 May; 32(5):1827-31. PubMed ID: 22593469
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
    Fujita Y, Hiramatsu M, Kawai M, Sumiyoshi K, Nishimura H, Tanigawa N.
    Dis Esophagus; 2008 May; 21(6):496-501. PubMed ID: 18840134
    [Abstract] [Full Text] [Related]

  • 10. Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot study.
    Laack E, Andritzky B, Dürk H, Burkholder I, Edler L, Schuch G, Boeters I, Görn M, Lipp R, Horst H, Popp J, Hossfeld DK.
    Onkologie; 2005 Dec; 28(12):647-50. PubMed ID: 16330888
    [Abstract] [Full Text] [Related]

  • 11. A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
    Nakajima Y, Kawada K, Tokairin Y, Hoshino A, Okada T, Kawano T.
    Dig Surg; 2018 Dec; 35(2):131-137. PubMed ID: 28554183
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer.
    Kanekiyo S, Takeda S, Nakajima M, Nishiyama M, Kitahara M, Shindou Y, Michihisa I, Abe T, Yoshino S, Hazama S, Nagano H.
    Anticancer Res; 2016 Apr; 36(4):1923-7. PubMed ID: 27069181
    [Abstract] [Full Text] [Related]

  • 14. [Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
    Zhang XD, Shen L, Li J, Li Y, Li J, Zhang XT, Jin ML.
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):474-7. PubMed ID: 17974288
    [Abstract] [Full Text] [Related]

  • 15. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, Bu CF, Yeh KH.
    Anticancer Res; 2002 Jun; 22(6B):3621-7. PubMed ID: 12552966
    [Abstract] [Full Text] [Related]

  • 16. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting.
    Osaka Y, Takagi Y, Hoshino S, Tachibana S, Tsuchida A, Aoki T.
    Dis Esophagus; 2006 Jun; 19(6):473-6. PubMed ID: 17069591
    [Abstract] [Full Text] [Related]

  • 17. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA, Hainsworth JD.
    J Clin Oncol; 2010 May 01; 28(13):2213-9. PubMed ID: 20351330
    [Abstract] [Full Text] [Related]

  • 18. A single-institute phase I/II trial combining nedaplatin dose escalation with a fixed dose of docetaxel for induction chemotherapy of oral squamous cell carcinoma.
    Miyazaki A, Kobayashi J, Yamamoto T, Kido Y, Takemura K, Abe M, Tomihara K, Dehari H, Nakamori K, Nagai I, Hiratsuka H.
    Oral Oncol; 2008 May 01; 44(5):471-6. PubMed ID: 17826308
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.